Model SPE-PHA-90 is a pharmaceutical-grade lipophilic extract obtained from mature Serenoa repens fruits and standardized as an active pharmaceutical ingredient for tablet, capsule, granule, oral liquid, and injectable processing. The extract consists primarily of C8–C18 saturated and unsaturated fatty acids, with the total fatty acid fraction specified at not less than 90.0% by GC-FID after saponification and methyl ester derivatization. Phytosterols, expressed as β-sitosterol, are controlled at not less than 0.25%. The material is differentiated from cosmetic and dietary supplement saw palmetto extracts by compliance with ICH Q3C residual solvent limits, ICH Q3D elemental impurity limits, USP <61> and USP <62> microbial method requirements, and a peroxide value held at ≤ 5.0 meq O₂/kg. Two product designations are available: SPE-PHA-90T for solid oral dosage forms, and SPE-PHA-90INJ for sterile emulsion pre-compounding. The solid oral grade is supplied as a pale amber waxy solid at controlled storage temperature 2–8°C; the injectable grade is supplied under nitrogen in Type III amber glass vials sealed with PTFE-lined caps.

Specification Surface and Analytical Burden

Pharmacopoeial harmonization for this lipophilic extract is not constrained to a single monograph because saw palmetto extract is positioned between herbal medicine compendia and standardized lipid excipients. The analytical burden therefore includes identification of the native fatty acid methyl ester profile by capillary GC, quantitative assay of total fatty acids, peroxide value, acid value, iodine value, water content, residual ethanol, and a pesticide screen specific to the fruit source. The specification surface is built as an orthogonal control because saw palmetto extract contains free fatty acids, ethyl esters, triglycerides, sterols, and small quantities of long-chain aliphatic alcohols. A one-dimensional total fatty acid assay is insufficient for injectable use; the pharma-grade material therefore includes a peroxide limit that is intentionally lower than the 10 meq/kg threshold sometimes accepted in food-grade oils, because peroxides can destabilize phospholipid emulsifiers during high-pressure homogenization. Identification is confirmed by comparing the relative retention times of lauric, oleic, myristic, and linoleic acid methyl esters against a certified reference; batch-to-batch variance in the oleic-to-lauric ratio is controlled within ± 1.5% absolute.

Batch release criteria also include acid value as an indicator of free fatty acid content. The pharmaceutical-grade material is typically supplied with an acid value within 140–180 mg KOH/g; values below 140 mg KOH/g indicate a higher ester content, which can reduce emulsification efficiency in injectable formulations. Values above 180 mg KOH/g correlate with elevated free fatty acids and require pH adjustment during wet granulation to avoid acid-catalyzed hydrolysis of croscarmellose sodium. The moisture specification is fixed at ≤ 0.5% because stored saw palmetto extract absorbs water slowly but can undergo lipolytic rancidity if water is present; for this reason, desiccant-loaded HDPE drums are used for bulk shipment.

Solid oral processing begins by converting the semisolid extract into a free-flowing adsorbate. At 20°C the material is a waxy solid; at 40°C it becomes a viscous amber oil that cannot be metered by standard gravity hoppers. In production-scale tablet manufacture, 30–45 wt% of the extract is granulated with porous silicon dioxide, microcrystalline cellulose, and dicalcium phosphate dihydrate in a high-shear mixer operated at impeller tip speed 6–8 m/s. Discharge is timed to keep the granulate below 35°C to prevent lipid phase separation. Drying is conducted in a fluid-bed dryer with inlet air at 40–45°C; final granule moisture is held below 2.5%. For capsule filling, the dried adsorbate is milled through a 0.8 mm screen and lubricated with 0.5 wt% sodium stearyl fumarate. Direct compression of the unprocessed extract is unsuitable because the waxy phase softens under compression heat and causes punch filming after fewer than 15 minutes of press operation.

What Limits Direct Compression When the Extract Load Exceeds 320 mg per Tablet?

At extract loads above 320 mg per tablet, the limiting variable is not blend uniformity but ejection force. The lipophilic extract coats microcrystalline cellulose particles, reduces interparticle friction, and transfers a higher residual die-wall force to the lower punch. On a rotary tablet press with 10.0 mm round convex tooling, the useful compression force is usually held below 25 kN; higher forces generate tablet edge picking and occasional lamination because the lipid phase undergoes elastic recovery after decompression. Formulation adjustment is required above this load: replacing 10–15 wt% of microcrystalline cellulose with spray-dried mannitol or pregelatinized starch reduces punch sticking, while crospovidone at 2.0–3.0 wt% maintains disintegration below 15 minutes in 0.1 M HCl at 37°C using USP <701>. The press speed is typically restricted to 20–40 rpm on a 16-station instrumented press so that the temperature at the punch face remains below the softening range of the extract. Published data for saw palmetto extract at loads above 400 mg is limited; therefore, feasibility trials must measure ejection force and punch-film temperature at the defined press speed.

For granule dosage forms, the extract is dispersed as a molten phase at 45°C and sprayed through a jacketed nozzle onto porous silica with a particle size of 50–150 μm in a ploughshare mixer. The extract-to-silica ratio is maintained between 1.0:1 and 1.5:1; higher extract loadings produce free surface oil and block a 0.8 mm sieve during classification. Spray-granulation can also be performed in a fluid-bed system with an aqueous lecithin-stabilized dispersion, provided that inlet air temperature is 55°C and product temperature remains at 38–42°C. Final granules are classified to 180–710 μm. Fines below 180 μm are recycled, and oversized granules above 710 μm are milled under low shear. Residual moisture is held below 2.0% to limit fungal growth in sachet packaging.

Oral liquid and semisolid fill applications require the extract to be pre-dispersed at 45°C in a carrier system consisting of 10 wt% polysorbate 80 and 20 wt% medium-chain triglycerides, then diluted with purified water under high-shear mixing. The resulting microemulsion concentrate passes through a 100 μm in-line strainer before final dilution. Because the extract is susceptible to oxidative rancidity, the aqueous vehicle should contain 0.05 wt% sodium metabisulfite or be blanketed with nitrogen; without an antioxidant, the peroxide value increases by more than 5 meq/kg during accelerated storage at 40°C/75% RH.

When Injectable Grade Requires Phospholipid Pre-Complexation

Injectable pre-compounding with SPE-PHA-90INJ requires the extract to be converted into an oil phase that can withstand homogenization and sterilization. The neat extract is not freely soluble in water-for-injection; simple aqueous dispersion produces coarse droplets larger than 50 μm. The extract is therefore blended at 45°C with phosphatidylcholine and medium-chain triglycerides under nitrogen to form a homogeneous oil phase. This oil phase is combined with an aqueous phase containing 2.25% w/v glycerol and processed in a rotor-stator at 10,000 rpm for 10 minutes to form a coarse emulsion. The coarse emulsion is then passed through a two-stage high-pressure homogenizer at 1,000–1,200 bar for 5–8 cycles, with the heat exchanger maintaining outlet temperature below 25°C. Terminal sterilization at 121°C for 15 minutes is not applied to phospholipid systems prone to hydrolysis; aseptic filtration through a 0.22 μm membrane is preferred for heat-sensitive formulations. Because the extract contains long-chain fatty acids that can compete for the interfacial film, the phospholipid-to-oil phase ratio is maintained at 1.2:1 to 1.5:1 w/w. Published data for saw palmetto extract in injectable lipid emulsions is limited, so phase separation, free fatty acid release, and globule-size distribution must be verified for each batch using USP <729>.

After sterile filtration, the oil phase must not exceed a mean droplet diameter of 200 nm

The mean droplet diameter is derived from the pharmacopoeial threshold for injectable lipid emulsions. USP <729> controls the intensity-weighted mean droplet diameter to <500 nm and the volume-weighted fraction above 5 μm to ≤ 0.05%. For saw palmetto extract-loaded emulsions, a tighter internal limit of ≤ 200 nm is assigned because the extract contains free fatty acids that can alter interfacial tension and accelerate coalescence during steam sterilization and storage. Emulsion batches are filtered through a 0.22 μm polyethersulfone membrane; the post-filtration globule-size distribution is measured by dynamic light scattering, and the 5 μm tail is quantified by light obscuration. If the mean droplet diameter exceeds 200 nm, the batch is rejected or reprocessed through the high-pressure homogenizer for two additional cycles. The filter area is specified at 0.4–0.6 m²/L of emulsion to reduce premature fouling caused by the lipophilic phase.

Conventional saw palmetto extracts sold for dietary supplement use are not automatically acceptable for pharmaceutical tablet, capsule, granule, or injectable manufacturing. The pharma-grade product differs in oxidative stability, elemental cleanliness, residual solvent documentation, and consistency of the phytosterol marker. A comparison is summarized below.

The key difference for oral solid dosage form use is the peroxide value. A supplement-grade extract with a peroxide value above 20 meq O₂/kg can oxidize during fluid-bed drying at 45°C, imparting rancid odor to tablets and accelerating degradation of oxidation-sensitive actives. For injectable work, the pharma-grade extract is additionally filtered to reduce particulate matter and is tested for bacterial endotoxin by USP <85>; the injectable grade is supplied in amber Type III glass vials sealed under nitrogen. These controls are unnecessary for topical or food use, but they become process-determining when the extract is incorporated into dosage forms that require disintegration, dissolution, or sterile filtration.